Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: A study from the myeloproliferative neoplasm subcommittee of the CMWP of the European group for blood and marrow transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 2, 2014, Pages 279-281

  Alchalby, Haefaa ^a   Zabelina, Tatjana ^a   Stübig, Thomas ^a   van Biezen, Anja ^b   Bornhäuser, Martin ^c   Di Bartolomeo, Paolo ^d   Beelen, Dietrich ^e   Cahn, Jean Yves ^f   Dreger, Peter ^g   Schroyens, William ^h   de Witte, Theo ⁱ   Olavarria, Eduardo ^j   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d Ospedale Civile   (Italy)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f HÔPITAL MICHALLON   (France)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j Instituto de Investigación Sanitaria de Navarra   (Spain)

more..

Author keywords

Allogeneic stem cell transplantation; Blast phase; Complete remission; Myelofibrosis; Transformed AML

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER INCIDENCE; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; KARYOTYPE; LOG RANK TEST; MALE; MALIGNANT TRANSFORMATION; MIDDLE AGED; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SURVIVAL RATE;

ALLOGENEIC STEM CELL TRANSPLANTATION; BLAST PHASE; COMPLETE REMISSION; MYELOFIBROSIS; TRANSFORMED AML;

ADULT; AGED; COHORT STUDIES; EUROPE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NEOPLASM RECURRENCE, LOCAL; PRIMARY MYELOFIBROSIS; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84893097175     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.10.027     Document Type: Article

References (15)

1. Barosi G., Hoffman R. Idiopathic myelofibrosis. Semin Hematol 2005, 42:248-258.
2. Mesa R.A., Silverstein M.N., Jacobsen S.J., et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999, 61:10-15.
3. Cervantes F., Tassies D., Salgado C., et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991, 85:124-127.
4. Mesa R.A., Li C.Y., Ketterling R.P., et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005, 105:973-977.
5. Abdulkarim K., Girodon F., Johansson P., et al. AML transformation in 56 patients with Ph- MPD in two well defined populations. Eur J Haematol 2009, 82:106-111.
6. Passamonti F., Rumi E., Caramella M., et al. Adynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008, 111:3383-3387.
7. Gangat N., Caramazza D., Vaidya R., et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. JClin Oncol 2011, 29:392-397.
8. Morel P., Duhamel A., Hivert B., et al. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blat phase in primary myelofibrosis: a study of 172 patients. Blood 2010, 155:4350-4355.
9. Vannucchi A.M., Lasho T.L., Guglielmelli P., et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013, 27:1861-1869.
10. Deeg H.J., Gooley T.A., Flowers M.E., et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003, 102:3912-3918.
11. Kröger N., Holler E., Kobbe G., et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2009, 114:5264-5270.
12. Cherington C., Slack J.L., Leis J., et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res 2012, 36:1147-1151.
13. Ciurea S.O., de Lima M., Giralt S., et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 2010, 16:555-559.
14. Alchalby H., Yunus D.R., Zabelina T., et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol 2012, 157:75-85.
15. Scott B.L., Gooley T.A., Sorror M.L., et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012, 119:2657-2664.